Calculating an estimate of tissue integrated activity in 18F-FDG PET imaging using one SUV value

Eric Laffon, Manuel Bardiès, Jacques Barbet, Roger Marthan, Eric Laffon, Manuel Bardiès, Jacques Barbet, Roger Marthan

Abstract

Background: A kinetic model analysis was recently proposed to estimate the 18F-fluorodeoxyglucose (18F-FDG) integrated activity in an arbitrary tissue that uses tracer uptake and release rate constants. The aim of the current theoretical paper was to estimate 18F-FDG integrated activity using one standardized uptake value (SUV).

Methods: A further kinetic model analysis allowed us to derive an analytical solution for integrated activity determination, involving both irreversible and reversible trapping. It only uses SUV, which is uncorrected for 18F physical decay (SUVuncorr, in g.mL-1) and is assessed about its peak value. Measurement uncertainty of the estimate was also assessed.

Results: In a tissue (volume V, in mL) that irreversibly traps 18F-FDG, the total number of disintegrations can be estimated as: ÃC = 162 * 105 * SUVuncorr * V * ID / W (ID, injected dose, in MBq; W, patient's weight, in kg), where SUVuncorr is a mean over V and is assessed between 55 and 110 min after tracer injection. The relative uncertainty ranges between 18% and 30% (the higher the uptake, the lower the uncertainty). Comparison with the previous Zanotti-Fregonara's model applied to foetus showed less than 16% difference. Furthermore, calculated integrated activity estimates were found in good agreement with Mejia's results for healthy brain, lung and liver that show various degrees of tracer trapping reversibility and various fractions of free tracer in blood and interstitial volume.

Conclusion: Estimation of integrated activity in an arbitrary tissue using one SUV value is possible, with measurement uncertainty related to required assumptions. A formula allows quick estimation that does not underestimate integrated activity so that it could be helpful in circumstances such as accidental exposure, or for epidemiologic purposes such as in patients having undergone several examinations.

Figures

Figure 1
Figure 1
Model comparison. Curve (a) Trapped tracer activity (in arbitrary unit) versus time (in minutes) from Equation 3, assuming irreversible trapping, and the input function of Vriens et al. for 18F-FDG was used [15]. Curve (b) (full line) Z-F function, i.e. ATot(t = 60) * exp(−λt) (the value for ATot(t=60) was taken from curve a). Curve (c) (dotted line) Z-F function with ATot(t = 84) (instead of ATot(t = 60)) that gives similar AUC for the two models.

References

    1. Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, Oster ZH, Sacker DF, Shiue CY, Turner H, Wan CN, Wolf AP, Zabinski SV. A fluorinated glucose analog, 2-fluoro-2-deoxy-d-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;3:670–675.
    1. Valk PE, Bailey DL, Townsend DW, Maisey MN. Positron Emission Tomography, Basic Science and Clinical Practice. London: Springer; 2002.
    1. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations (revised). Ed. New York: The Society of Nuclear Medicine; 1991.
    1. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry - standardization of nomenclature. J Nucl Med. 2009;3:477–484.
    1. Hays MT, Watson EE, Thomas SR, Stabin M. Radiation absorbed dose estimates from 18F-FDG. MIRD dose estimate report no. 19. J Nucl Med. 2002;3:210–214.
    1. Annals of the ICRP 106. Radiation dose to patients from radiopharmaceuticals. ICRP Publication. 2008;3(1–2):85.
    1. Zanotti-Fregonara P, Champion C, Trebossen R, Maroy R, Devaux J-Y, Hindié E. Estimation of the β+ dose to the embryo resulting from 18F-FDG administration during early pregnancy. J Nucl Med. 2008;3:679–682.
    1. Zanotti-Fregonara P, Jan S, Taieb D, Cammilleri S, Trebossen R, Hindié E, Mundler O. Absorbed 18F-FDG dose to the foetus during early pregnancy. J Nucl Med. 2010;3:803–805.
    1. Laffon E, Bardiès M, Barbet J, Marthan R. Kinetic model analysis for absorbed dose calculation applied to brain in [18F]-FDG PET imaging. Cancer Biother Radiopharm. 2010;3:665–669.
    1. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-d-glucose: validation of method. Ann Neurol. 1979;3:371–388.
    1. Mejia AA, Nakamura T, Masatoshi I, Hatazawa J, Masaki M, Watanuki S. Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J Nucl Med. 1991;3:699–706.
    1. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;3:11S–20S.
    1. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;3:897–916.
    1. Hunter GJ, Hamberg LM, Alpert NM, Choi NC, Fischman AJ. Simplified measurement of deoxyglucose utilization rate. J Nucl Med. 1996;3:950–955.
    1. Vriens D, de Geus-Oei L-F, Oyen WJG, Visser EP. A curve-fitting approach to estimate the arterial plasma input function for the assessment of glucose metabolic rate and response to treatment. J Nucl Med. 2009;3:1933–1939.
    1. Diem K, Lentner C. Composition chimique du corps humain. 7. Basle: Ciba-Geigy SA; 1978. p. 528. (In Tables Scientifiques).
    1. Minamimoto R, Takahashi N, Inoue T. FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues. Ann Nucl Med. 2007;3:217–222.
    1. Laffon E, de Clermont H, Vernejoux J-M, Jougon J, Marthan R. Feasibility of assessing [(18)F]FDG lung metabolism with late dynamical imaging. Mol Imaging Biol. 2011;3:378–384.
    1. Laffon E, Adhoute X, de Clermont H, Marthan R. Is liver SUV stable over time in 18F-FDG PET imaging? J Nucl Med Technol. 2011;3:1–6.
    1. Hapdey S, Buvat I, Carson JM, Carrasquillo JA, Whatley M, Bacharach SL. Searching for alternatives to full kinetic analysis in 18F-FDG PET: an extension of the simplified kinetic analysis method. J Nucl Med. 2011;3:634–641.
    1. de Langen AJ, Vincent A, Velasquez LM, van Tinteren H, Boellaard R, Shankar LK, Boers M, Smit EF, Stroobants S, Weber WA, Hoekstra OS. Repeatability of 18F-FDG uptake measurements in tumours: a meta-analysis. J Nucl Med. 2012;3:701–708.
    1. Takalkar AM, Khandelwal A, Lokitz S, Lilien DL, Stabin MG. 18F-FDG PET in pregnancy and fetal radiation dose estimate. J Nucl Med. 2011;3:1035–1040.
    1. Laffon E, Cazeau A-L, Monet A, de Clermont H, Fernandez P, Marthan R, Ducassou D. The effect of renal failure on 18FDG uptake: a theoretic assessment. J Nucl Med Technol. 2008;3:200–202.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅